




CHALLENGES

REFERENCES

1. Sheibani K, Nathwani BN, Winberg CD, et al. Antigenically defined subgroups of lymphoblastic lymphoma. *Cancer* 1987;60:183-190.
2. Lin P, Jones D. et al. Precursor B-cell lymphoblastic lymphoma. *Am J Surg Pathol* 2000; 24:1480-1490.
3. Maitra A, McKenna RW, et al. Precursor B-cell lymphoblastic lymphoma. *Am J Clin Pathol* 2001;115:868-875.
4. Rozman C, Montserrat E. Chronic lymphocytic leukemia. *N Engl J Med* 1995;333:1052-1057.
5. Lennert K, Feller AC. Histopathology of non-Hodgkin's lymphomas (based on the updated Kiel Classification), 2nd ed. New York: Springer-Verlag, 1992:54-60.
6. Batata A, Shen B. Relationship between chronic lymphocytic leukemia and small lymphocytic lymphoma. *Cancer* 1992;70:625-632.
7. Finkel HE, Raje N. Case 27-2001: Waldenstrom's macroglobulinemia. *N Engl J Med* 2002;346:784.
8. McCurley TL, Collins RD, Ball E, et al. Nodal and extranodal lymphoproliferative disorders in Sjogren syndrome: a clinical and immunopathologic study. *Hum Pathol* 1990;21:482-492.
9. Andriko JA, Swardlow SH, et al. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? *Am J Surg Pathol* 2001;25(6):742-751.
10. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma: a proposal for unification of morphologic, immunologic, and molecular data. *Am j Surg Pathol* 1992; 16:637-640.
11. Yatabe Y, Suzuki R, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL, and cyclin D1 negative MCL-like B-cell lymphoma. *Blood* 2000; 95(7):2253-2261.
12. Liu Z, Dong HY, Gorczyca W, et al. CD5-mantle cell lymphoma. *Am J Clin Pathol* 2002;118:216-224.
13. Sanchez ML, Almeida J, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. *Leukemia* 2002;16(8):1460-1469.
14. Ngan BY, Warnke RA, et al. Monocytoid B-cell lymphoma: a study of 36 cases. *Hum Pathol* 1991;22(5):409-421.
15. Nathwani BN, Drachenberg MR, et al. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma). *Semin Hematol* 1999;36(2): 128-138.
16. Hammer RD, Glick AD, Greer JP, et al. Splenic marginal zone lymphoma: a distinct B cell neoplasm. *Am J Surg Pathol* 1996;20:613-626.
17. Van Huyen JPD, Molina T, et al. Splenic marginal zone lymphoma with or without plasmacytic differentiation. *Am J Surg Pathol* 2000;24(12):1581-1592.
18. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. *Helicobacter pylori* associated gastritis and primary B-cell gastric lymphoma. *Lancet* 1991;338:1175-1176.

19. Cavalli F, Isaacson PG et al. MALT lymphomas. *Hematology* 2001;241(1):1-30.
20. Papadaki L, Wotherspoon AC, Isaacson PG. The lymphoepithelial lesion of gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue (MALT): an ultrastructural study. *Histopathology* 1992;21:415-421.
21. Isaacson PG, Wotherspoon AC, Diss T, et al. Follicular colonization in B-cell lymphoma of mucosa-associated lymphoid tissue. *Am J Surg Pathol* 1991; 15: 819-828.
22. Chan JKC, Ng CS, Isaacson PG. Relationship between high-grade lymphoma and low grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. *Am J Pathol* 1990; 136: 1153-1164.
23. Goodlad JR, Krajewski AS, et al. Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity. *Am J Surg Pathol* 2002;26(6):733-741.
24. Weisenburger DD, Chan WC. Lymphomas of follicles. Mantle cell and follicle center cell lymphomas. *Am J Clin Pathol* 1993; 99: 409-420.
25. Yegappan S, Schnitzer B, et al. Follicular lymphoma with marginal zone differentiation: microdissection demonstrates the t(14;18) in both the follicular and marginal zone components. *Mod Pathol* 2001; 14:191.
26. Ott G, Katzenberger T, et al. Cytomorphologic, immunohistochemical and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. *Blood* 2002;99:3806-3812.
27. Harris NL, Nadler LM, Bhan AK. Immunohistologic characterization of two malignant lymphomas of germinal center type (centroblastic/centrocytic and centrocytic) with monoclonal antibodies. *Am J Pathol* 1984; 117:262-272.
28. Esho C, Perkins S, et al. Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas. *Am J Clin Pathol* 2001; 115:862-867.
29. Berekman CL, Aguilera NSI, et al. Low-grade B-cell lymphoma with co-expression of both CD5 and CD10. *Arch Pathol Lab Med* 2001;125:951-953.
30. Sandlund JT, Downing JR, Crist WM. Non-Hodgkin's lymphoma in childhood. *N Engl J Med* 1996;334:1238-1248.
31. Pavlova Z, Parker JW, Taylor CR, et al. Small noncleaved follicular center cell lymphoma: Burkitt's and non-Burkitt's variants in the US. *Cancer* 1987;59:1892-1902.
32. Mashal RD, Canellos GP. Small non-cleaved lymphoma in adults. *Am J Hematol* 1991;38:40-47.
33. Coiffier B. Diffuse Large cell lymphoma. *Curr Opin Oncol* 2001;13:325-334.
34. O'Hara CJ, Said JW, Pinkus GS. Non-1 Hodgkin's lymphoma, multilobated B-cell type: report of nine cases with immunohistochemical and immunoelectron microscopic evidence for a follicular center cell derivation. *Hum Pathol* 1986;17:393-599.
35. King BE, Chen C, et al. Immunophenotypic and genotypic markers of follicular center cell neoplasia in diffuse large B-cell lymphomas. *Mod Pathol* 2000;13:1219-1231.
36. Yamaguchi M, Seto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. *Blood* 2002;99(3):815-821

37. Lazzarino M, Orlandi E, Paulli M, et al. Primary mediastinal B-cell lymphoma with sclerosis: an aggressive tumor with distinctive clinical and pathologic features. *J Clin Oncol* 1993;11:2306-2313.
38. Perrone T, Frizzera G, Rosai J. Mediastinal diffuse large-cell lymphoma with sclerosis. *Am J Surg Pathol* 1986;10:176-191.
39. Suster S. Primary large-cell lymphomas of the mediastinum. *Semin Diagn Pathol* 1999;16 (1)-51-64,
40. Carroll TJ, Schelper RL, Goeken JA, et al. Neoplastic angioendotheliomatosis: immunopathologic and morphologic evidence for intravascular malignant lymphomatosis. *Am J Clin Pathol* 1986;85:169-175.
41. Ferry JA, Harris NL, Picker LJ, et al. Intravascular lymphomatosis (malignant angioendotheliomatosis): a B-cell neoplasm expressing surface homing receptors. *Mod Pathol* 1988;1:444-452.
42. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. *Blood* 1995;85:2654-2670.
43. Harris NL, Jaffe ES, Stein H, et al. Lymphoma classification proposal: clarification. *Blood* 1995;85:857-860.
44. Nathwani BN, Diamond LW, Winberg CD. Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. *Cancer* 1981;48:2347-2357.
45. Bernard A, Boumsell L, Reinherz L, et al. Cell surface characterization of malignant T cell from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. *Blood* 1981;57:1105-1110.
46. Mori N, Oka K, Yoda Y, et al. Leu-4 (CD3) antigen expression in the neoplastic cells from T- ALL. and T lymphoblastic lymphoma. *Am J Clin Pathol* 1988;90:244-249.
47. Weiss L, Bindl J, Picozzi V, et al. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia *Blood* 1986;67:474-478.
48. Waldron JA leech JH, Glick AD, et al. Malignant lymphoma of peripheral T-lymphocyte origin: immunologic, pathologic, and clinical features in six patient *Cancer* 1977;40:1604-1617.
49. Tsimberidou AM, Giles F, Duvic M, et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an MD Anderson Cancer Center series. *Cancer* 2004; 100:342-49.
50. Smith BD, Wilson LD. Management of mycosis fungoides: part 2, treatment. *Oncology (Huntingt)* 2003; 17: 1419-28.
51. Patsouris E, Noel H, Lernert K. Histological and immunohistological findings in lymphoepithelioid cell lymphoma (Lennert's lymphoma). *Am J Surg Pathol* 1988;12:341-350.
52. Kojima M, Nakamura S, Mohniri T, et al. Centroblastic and centroblastic-centrocytic lymphomas associated with prominent epithelioid granulomatous response without plasma cell differentiation: a clinicopathologic study of 12 cases. *Hum Pathol* 1996;27:660-667.
53. Lukes RJ, Tindle BH. "Immunoblastic lymphadenopathy," a hyper immune entity resembling Hodgkin's disease. *N Engl J Med* 1975; 292:1-8.
54. Stein H, Mason D, Cerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence

- that Reed-Stenberg cells and histiocytic malignancies are derived from activated lymphoid cells. *Blood* 1985;66:848-858.
55. De Bnain P, Beljaards R, van Heerde P, et al. Differences in clinical behavior and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T-cell or null cell phenotype. *Histopathology*. 1993;23:127-135.
 56. Kaudewilz P, Stein H, Dallenbach F. Primary and secondary KJ-1 + (CD30+) anaplastic large cell lymphomas. *Am J Pathol* 1989;135:359-367.
 57. Piris M, Brown D, Gatter K, et al. CD30 expression in non-Hodgkin's lymphoma. *Histopathology* 1990; 17:211-218.
 58. Salhany KF, Feldman M, Peritt D, et al. Hepatosplenic T-cell lymphoma: ultra structural, immunophenotypic and functional evidence for cytotoxic T lymphocyte (CIL) differentiation. *Hum Pathol* 1997;28:674-685.
 59. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtype-. *Am J Surg Pathol* 1998;22:881-893.
 60. O'Farrelly C, Frighery C, O'Brian DS, et al. Humoral response to wheat protein in patients with celiac disease and enteropathy associated T-cell lymphomas. *Br Med J* 1986;293:908-910.
 61. Emile J-F, Bulland M-L, Haiouin C, et al. CD56 T-cell receptor silent - T-cell lymphomas natural killer cell lymphomas. *Blood* 1996;87:1466-1473.
 62. Sun T, Brody J, Susin M, et al. Aggressive natural killer cell lymphoma/ leukemia. A recently, recognized clinicopathologic entity. *Am Surg Pathol* 1993; 17: 1289-1299.
 63. Imamura N, Kusunoki, Kawa.Ha K, et al. Aggressive natural killer cell leukemia lymphomas report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. *Br J Hematol* 1990; 75: 49-59.
 64. Regula DP, Hoppe RT, Weiss LM. Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. *N Engl J Med* 1988;318:214-219
 65. Strum SB, Rappaport H. Consistency of histologic subtypes in Hodgkin's disease in simultaneous and sequential biopsy specimens. *Natl Cancer Inst Monogr* 1973;36:253-260.
 66. Bennett MH, Tu A, Hodgson GV. Analysis of grade I Hodgkin's disease (Report No. 6):cellular subtypes related to prognosis. *Clin Radio!* 1981;32:491-498.
 67. Wolf J, Diehl V. Is Hodgkin's disease an infectious disease? *Ann Oncol* 1994;5 Suppl:105-III.
 68. Kadin ME, Stites DP, Levy R, Warnke R. Exogenous immunoglobulin and the macrophage origin of Reed-Stenberg cells in Hodgkin's disease. *N Engl J Med* 1978;299:1208-1214.
 69. Diehl V, vonKalle C, Fonatsch C, et al. The cell of origin of Hodgkin's disease. *Semin Oncol* 1990;17:660-672.
 70. Agnarsson BA, Kadin ME. The immunophenotype of Reed-Stenberg cells: a study of 50 cases of Hodgkin's disease using fixed frozen tissues. *Cancer* 1989;63:2083-2087.
 71. Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt's lymphoma and leukemia. *Curr Opin Oncol* 2004;16: 429-435.

72. Jaffe E, Harris N, Stein H, et al. World Health Organization Classification of Tumours: Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Geneva, Switzerland: World Health Organization; 2001.
73. Winter J, Gascoyne R, Van Besien K. Low grade lymphoma. Hematology (American Society of Hematology Education Program). 2004;203-220.
74. American Joint Committee on Cancer. AJCC Cancer Staging Handbook. Philadelphia, PA; Lippincott; 1998; p 264.
75. Ganti AK, Bociek RG, Bierman PJ, et al. Follicular lymphoma: expanding therapeutic options. Oncology 2005;19: 213-228.
76. International Non-Hodgkin's Lymphoma Prognostic Factor Project members. A predictive model for aggressive non-Hodgkin's lymphoma-The International Non-Hodgkin's Lymphoma Prognostic Factor Project. N Engl J Med 1993;329:987-994.
77. Nadler L, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res.1980;40:3137-3154.
78. Longo D. Immunotherapy for non-Hodgkin's lymphoma. Curr Opin Oncol . 1996;8:353-359.
79. Giennie MJ, Johnson PWM. Clinical trials of antibody therapy. Immunol Today 2000;21:403-410.
80. McLaughlin p, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
81. Davis TA, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-1857.
82. Davis TA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-3143.
83. Vose JM, et al. Phase II study of rituximab in combination with CHO chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-397.
84. Press OW. et al. Immunotherapy of non-Hodgkin's lymphomas. Hematology 2001;221-240.
85. Keating MJ. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561.
86. Sirisinha S, Eisen H. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Proc Natl Acad Sci US A 1971 ;68:3130-3135.
87. Lynch R, et al. Myeloma proteins as tumor specific transplantation antigens. Proc Natl Acad Sci U S A 1972;69:1540-1544.
88. Levy R, Miller R. therapy of lymphoma directed at idiotypes. Monogr Natl Cancer Inst 1999;10:61-68.
89. Thielemans K, et al. Strategies for production of monoclonal anti idiotypic antibodies against human B cell lymphomas. J Immunol 1984; 133:495-501.
90. Miller R, et al. Treatment of B cell lymphoma with monoclonal anti-idiotypic antibody. N Engl J Med 1982;306:517-522.
91. Meeker T, et al. A clinical trial of anti-idiotypic therapy for B cell malignancy. Blood 1985;65:349-353.

92. Meeker T. et al. Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. *N Engl Med* 1985;312:1658-1665.
93. Press; OW, Rasey J. Principles of radioimmunotherapy for hematologists and oncologist *Semin Oncol* 2000;27-62-71
94. Ghetie MA, Vitetta E. Recent developments in immunotoxin therapy. *Curr Opin Immunol* 1994; 6:707-714.
95. Renner C. Pfrenudschuh M. Tumor therapy by immune recruitment with Bispecific antibodies *Immunol Rev* 1995;145:179-209.
96. Darnell J, Kerr I. Stark G. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 1994;264:1415-5020.
97. Gresser I. et al. Interferon and murine leukemia: V. Effect of interferon preparations on the evolution of Rauscher disease in mice. *I Natl Cancer Inst* 1968;41:505-522.
98. Gresser I, Bourali C. Exogenous interferon and inducers of interferon in the treatment of BALB/c mice inoculated with RC19 tumour cells. *Nature* 1969;223-844-845.
99. Lotze M, et al. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. *Cancer Res* 1981 ;41:4420-1425.
100. Kolb H, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. *Blood* 1995;86:2041-2050.
101. Kolb H, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients *Blood* 1990;76:2462-2465.
102. Giralt S, Kolb H. Donor lymphocyte infusion. *Curr Opin Oncol* 1996;8:96-102.
103. Rosenberg S, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 1985;313:1485-1492.
104. Rayner A, et al. Lymphokine-activated killer (LAK) cell phenomenon, analysis of factors relevant to the immunotherapy of human cancer. *Cancer* 1985;55:1327-1333.
105. Rosenberg S, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N Engl J Med* 1987;316:889-897.
106. Kwak L., et al . Induction of immune responses in patients with B-cell lymphoma against the surface immunoglobulin idiotype expressed by their tumors *N Engl I Med* 1992;327-1209- 1215.
107. Pardoll, D. Paracrine cytokine adjuvants in cancer immunotherapy. *Annu Rev Immunol* 1995;13:399-415.
108. Marvin J Stone *Medicine and Creativity Vol 368 December 2006 Lancet* 2006; 368: S48-S49
109. Veronese ML, O'Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. *Eur J Cancer* 2004;40:1292-301.
110. Trail PA, King HD, Dubowchik GM. Monoclonal antibody drug immunoconjugates for targeted treatment of cancer. *Cancer Immunol Immunother* 2003;52:328-37.

111. Trikha M, Yan L, Nakada MT. Monoclonal antibodies as therapeutics in oncology. *Curr Opin Biotechnol* 2002;13:609–14.
112. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. *Trends Mol Med* 2002;8:17–23.
113. Hicklin DJ, Witte L, Zhu Z, Liao F, Wu Y, Li Y, et al. Monoclonal antibody strategies to block angiogenesis. *Drug Discov Today* 2001;6:517–28.
114. W.H. Fridman, F.M. Kourilsky, Stimulation of lymphocytes by autologous leukaemic cells in acute leukaemia, *Nature* 224 (1969) 277–279.
115. F. Pages, A. Berger, M. Camus, F. Sanchez-Cabo, A. Coste, R. Molitor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, T. Meatchi, P. Bruneval, P.-H. Cugnenc, Z. Trajanoski, W.H. Fridman, J. Galon, Effector memory T cells, early metastasis, and survival in colorectal cancer, *N. Engl. J. Med.* 353 (2005) 2654–2666.
116. Benhar I, Azriel R, Nahary L, Shaky S, Berdichevsky Y, Tamarkin A, et al. Highly efficient selection of phage antibodies mediated by display of antigen as LppOmpA' fusions on live bacteria. *J Mol Biol* 2000;301:893–904.
117. Hoogenboom HR. Overview of antibody phage-display technology and its applications. *Methods Mol Biol* 2002;178:1–37.
118. Worn A, Pluckthun A. Stability engineering of antibody single-chain Fv fragments. *J Mol Biol* 2001;305:989–1010.
119. von Mehren M, Adams GP, Weiner LM. Monoclonal antibody therapy for cancer. *Annu Rev Med* 2003;54:343–69.
120. Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, et al. Single-chain antigen-binding proteins. *Science* 1988;242:423–6.
121. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. *Cancer Res* 1992;52:3402–8.
122. Kreitman RJ. Immunotoxins in cancer therapy. *Curr Opin Immunol* 1999;11:570–8.
123. Reiter Y, Brinkmann U, Lee B, Pastan I. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. *Nat Biotechnol* 1996;14:1239–45.
124. Peipp M, Valerius T. Bispecific antibodies targeting cancer cells. *Biochem Soc Trans* 2002;30:507–11.
125. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. *Nat Rev Drug Discov* 2003;2:52–62.
126. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HABA) responses to monoclonal antibodies. Not four letter words. *Q J Nucl Med Mol Imaging* 2004;48:251–7.
127. Kim JA. Targeted therapies for the treatment of cancer. *Am J Surg* 2003;186:264–8.
128. Kreitman RJ. Recombinant toxins for the treatment of cancer. *Curr Opin Mol Ther* 2003;5:44–51.
129. Pastan I, Kreitman RJ. Immunotoxins in cancer therapy. *Curr Opin Investig Drugs* 2002;3:1089–91.
130. Jain RK. Delivery of molecular medicine to solid tumors. *Science* 1996;271:1079–80.
131. Pastan I, Beers R, Bera TK. Recombinant immunotoxins in the treatment of cancer. *Methods Mol Biol* 2004;248:503–18.

132. Gatto B. Monoclonal antibodies in cancer therapy. *Curr Med Chem Anti-Cancer Agents* 2004;4:411–4.
133. Law CL, Cervený CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates. *Clin Cancer Res* 2004;10:7842–51.
134. DeNardo SJ, DeNardo GL, Brush J, Carter P. Phage library-derived human anti-TETA and anti-DOTA ScFv for pretargeting RIT. *Hybridoma* 1999;18:13–21.
135. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. *Cancer Biol Ther* 2004;3:361–70.
136. S. Sacchi et al. : Critical Reviews in Oncology:Hematology 37 (2001) 13–25
137. Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-CD20 antibody. *J Immunol* 1990;144:1382–6.
138. Tedder TF, Forsgren A, Boyd AW, Nadler LM, Schlossman SF. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes. *Eur J Immunol* 1987;16:881–7.
139. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse:human chimeric monoclonal antibody in man: kinetics and immune response. *Proc Natl Acad Sci* 1989;86:4220–4.
140. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptors predicts a hydrophobic protein with multiple transmembrane domains. *EMBO J* 1988;7:711–7.
141. Teeling, J.L., Mackus, W.J., Wiegman, L.J., van den Brakel, J.H., Beers, S.A., French, R.R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J.W., Parren, P.W., Glennie, M.J., van de Winkel, J.G., 2006. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. *J. Immunol.* 177, 362–371.
142. Cragg, M.S., Glennie, M.J., 2004. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. *Blood* 103, 2738–2743.
143. Cragg, M.S., Walshe, C.A., Ivanov, A.O., Glennie, M.J., 2005. The biology of CD20 and its potential as a target for mAb therapy. *Curr. Dir. Autoimmun.* 8, 140–174.
144. Nimmerjahn, F., Ravetch, J.V., 2007. Antibodies Fc receptors and cancer. *Curr. Opin. Immunol.* 19, 239–245.
145. Nimmerjahn, F., Ravetch, J.V., 2006. Fc gamma receptors: old friends and new family members. *Immunity* 24, 19–28.
146. Desai, D.D., Harbers, S.O., Flores, M., Colonna, L., Downie, M.P., Bergtold, A., Jung, S., Clynes, R., 2007. Fc{gamma} receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. *J. Immunol.* 178, 6217–6226.
147. Uchida, J., Hamaguchi, Y., Oliver, J.A., Ravetch, J.V., Poe, J.C., Haas, K.M., Tedder, T.F., 2004. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. *J. Exp. Med.* 199, 1659–1669.
148. Bevaart, L., Jansen, M.J., van Vugt, M.J., Verbeek, J.S., van de Winkel, J.G., Leusen, J.H., 2006. The high-affinity IgG receptor, Fc gamma

- RI, plays a central role in antibody therapy of experimental melanoma. *Cancer Res.* 66, 1261–1264.
149. Fossati-Jimack, L., Ioan-Facsinay, A., Reininger, L., Chicheportiche, Y., Watanabe, N., Saito, T., Hofhuis, F.M., Gessner, J.E., Schiller, C., Schmidt, R.E., Honjo, T., Verbeek, J.S., Izui, S., 2000. Markedly different pathogenicity of four immunoglobulin G isotype-switch variants of an antierythrocyte autoantibody is based on their capacity to interact in vivo with the low-affinity Fc gamma receptor III. *J. Exp. Med.* 191, 1293–1302.
150. Gong, Q., Ou, Q., Ye, S., Lee, W.P., Cornelius, J., Diehl, L., Lin, W.Y., Hu, Z., Lu, Y., Chen, Y., Wu, Y., Meng, Y.G., Gribbling, P., Lin, Z., Nguyen, K., Tran, T., Zhang, Y., Rosen, H., Martin, F., Chan, A.C., 2005. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. *J. Immunol.* 174, 817–826.
151. Hamaguchi, Y., Uchida, J., Cain, D.W., Venturi, G.M., Poe, J.C., Haas, K.M., Tedder, T.F., 2005. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. *J. Immunol.* 174, 4389–4399.
152. Anolik, J.H., Campbell, D., Felgar, R.E., Young, F., Sanz, I., Rosenblatt, J., Looney, R.J., 2003. The relationship of Fc gamma RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. *Arthritis Rheum.* 48, 455–459.
153. Golay, J., Cittera, E., Di Gaetano, N., Manganini, M., Mosca, M., Nebuloni, M., van Rooijen, N., Vago, L., Introna, M., 2006. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. *Haematologica* 91, 176–183.
154. Kennedy, A.D., Beum, P.V., Solga, M.D., DiLillo, D.J., Lindorfer, M.A., Hess, C.E., Densmore, J.J., Williams, M.E., Taylor, R.P., 2004. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. *J. Immunol.* 172, 3280–3288.
155. Treon, S.P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., Anderson, K.C., 2001. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. *J. Immunother.* 24, 263–271.
156. Idusogie, E.E., Presta, L.G., Gazzano-Santoro, H., Totpal, K., Wong, P.Y., Ultsch, M., Meng, Y.G., Mulkerrin, M.G., 2000. Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc. *J. Immunol.* 164, 4178–4184.
157. Coiffier, B., 2006. Monoclonal antibody as therapy for malignant lymphomas. *C.R. Biol.* 329, 241–254.
158. Kumar, V., Ali, S.R., Konrad, S., Zwirner, J., Verbeek, J.S., Schmidt, R.E., Gessner, J.E., 2006. Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. *J. Clin. Invest.* 116, 512–520.
159. Huber-Lang, M., Sarma, J.V., Zetoune, F.S., Rittirsch, D., Neff, T.A., McGuire, S.R., Lambris, J.D., Warner, R.L., Flierl, M.A., Hoesel, L.M., Gebhard, F., Younger, J.G., Drouin, S.M., Wetsel, R.A., Ward, P.A., 2006. Generation of C5a in the absence of C3: a new complement activation pathway. *Nat. Med.* 12, 682–687.
160. Atkinson, J.P., 2006. C5a and Fc gamma receptors: a mutual admiration society. *J. Clin. Invest.* 116, 304–306.

161. Hong, F., Yan, J., Baran, J.T., Allendorf, D.J., Hansen, R.D., Ostroff, G.R., Xing, P.X., Cheung, N.K., Ross, G.D., 2004. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. *J. Immunol.* 173, 797–806.
162. Bowles, J.A., Wang, S.Y., Link, B.K., Allan, B., Beuerlein, G., Campbell, M.A., Marquis, D., Ondek, B., Wooldridge, J.E., Smith, B.J., Breitmeyer, J.B., Weiner, G.J., 2006. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. *Blood* 108, 2648–2654.
163. Jackell, H.P., Trabandt, A., Grobe, N., Werle, E., 2006. Anti-dsDNA antibody subtypes and anti-C1q antibodies: toward a more reliable diagnosis and monitoring of systemic lupus erythematosus and lupus nephritis. *Lupus* 15, 335–345.
164. Botto, M., Introna, M., Golay, J., 2003. Complement activation determines the therapeutic activity of rituximab in vivo. *J. Immunol.* 171, 1581–1587.
165. Lopes de Menezes, D.E., Denis-Mize, K., Tang, Y., Ye, H., Kunich, J.C., Garrett, E.N., Peng, J., Cousens, L.S., Gelb, A.B., Heise, C., Wilson, S.E., Jallal, B., Aukerman, S.L., 2007. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma. *J. Immunother.* 30, 64–74. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. *J. Clin. Oncol.* 16, 2825–2833.
166. Song, S., Crow, A.R., Siragam, V., Freedman, J., Lazarus, A.H., 2005. Monoclonal antibodies that mimic the action of anti-D in the amelioration of murine ITP act by a mechanism distinct from that of IVIg. *Blood* 105, 1546–1548.
167. Taylor, R.P., Li, Y., Lindorfer, M.A., Coursar, J.B., Williams, M.E., 2006. Flow cytometry and immunohistochemistry analyses reveal that rituximab/CD20 complexes are removed (shaved) from mantle cell lymphoma cells (Z138) previously infused intravenously or subcutaneously in a SCID mouse model, and the shaving reaction can be blocked by IVIG. *ASH Annual Meeting Abstracts* 108, p. 2105.
168. Klepfish, A., Schattner, A., Ghoti, H., Rachmilewitz, E.A., 2007. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. *Lancet Oncol.* 8, 361–362.
169. Davis, W., Harrison, P.T., Hutchinson, M.J., Allen, J.M., 1995. Two distinct regions of FC gamma RI initiate separate signalling pathways involved in endocytosis and phagocytosis. *EMBO J.* 14, 432–441.
170. Glennie, M.J., Cragg, M.S., 2003. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. *Cancer Res.* 63, 5480–5489.
171. M.R. Smith, Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance, *Oncogene* 22 (2003) 7359–7368.
172. S.P. Bohen, O.G. Troyanskaya, O. Alter, R. Warnke, D. Botstein, P.O. Brown, R. Levy, Variation in gene expression patterns in follicular lymphoma

- and the response to rituximab, *Proc. Natl Acad. Sci. USA* 100 (2003) 1926–1930
173. Maloney DG, Liles TM, Czerwinski DK, Rosenberg J, Grillo-Lopez A, Levy R. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. *Blood* 1994;84:2457–66.
 174. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. *Ther Drug Monit* 2000;22:295–301.
 175. Mangel J, Buckstein R, Imrie K, et al. Pharmacokinetic study of patients with follicular or mantle cell lymphoma treated with rituximab as “in vivo purge” and consolidative immunotherapy following autologous stem cell transplantation. *Ann Oncol* 2003;14:758–65.
 176. Regazzi MB, Iacona I, Avanzini MA, et al. Pharmacokinetic behaviour of rituximab. A study of different schedules of administration for heterogenous clinical settings. *Ther Drug Monit* 2005;27:785–92.
 177. Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of (131)I-labelled anti CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin’s lymphoma. *Eur J Nucl Med Mol Imaging* 2002;29:1276–82.
 178. Tobinai K, Kobayashi Y, Narabayashi M, et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. *Ann Oncol* 1998;9:527–34.
 179. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. *Ann Oncol* 1998;9:995–1001.
 180. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. *J Clin Oncol* 1997;15:3266–74.
 181. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. *Blood* 1998;92:1927–32.
 182. O’Brien SM, Kantarjina H, Thomas DA, et al. Rituximab dose escalation trial in chronic lymphocytic leukaemia. *J Clin Oncol* 2001;19:2165–70.
 183. Aviles A, Leon MI, Diaz-Maqueo JC, Garcia EL, Cleto S, Neri N. Rituximab in the treatment of refractory follicular lymphoma—six doses are better than four. *J Hematother Stem Cell Res* 2001;10:313–6.
 184. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. *Ann Oncol* 1999;10:655–61.
 185. Byrd JC, Murphy T, Howard RS, et al. Rituximab using thrice weekly dosing schedule in B-cell chronic Lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. *J Clin Oncol* 2001;19:2153–64.
 186. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. *N Engl J Med* 2002;346:235–42.

187. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of prospective randomized study of the German Low-Grade Lymphoma Study Group. *Blood* 2005;106:3725-32.
188. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared to CVP as first-line treatment for advanced follicular lymphoma. *Blood* 2005;105:1417-23.
189. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low grade B-cell lymphoma with combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. *J Clin Oncol* 1999;17:268-76.
190. Ogura M, Morishima Y, Kagami Y, et al. Randomized phase II study of concurrent and sequential rituximab and CHOP chemotherapy in untreated indolent B-cell lymphoma. *Cancer Sci* 2006;97:305-12.
191. Habermann TM, Weller E, Morrisson VA, et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): an update. *Blood* 2004;104:40a [abstract 127].
192. Hainsworth JD, Litchy S, Burris HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. *J Clin Oncol* 2002;20:4261-7.
193. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. *J Clin Oncol* 2005;23:1096-102.
194. Scheinfeld N: A review of rituximab in cutaneous medicine. *Dermatol Online J* 12:3, 2006
195. Chung L, Funke AA, Chakravarty EF, et al: Successful use of rituximab for cutaneous vasculitis. *Arch Dermatol* 142:1407-1410, 2006
196. Sera T, Hiasa Y, Michitaka K, et al: Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. *Intern Med* 45: 721-724, 2006
197. Coiffier B: Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of Lamivudine prophylaxis. *Cancer Invest* 24:548-552, 2006
198. Hainsworth JD, Litchey S, Morrissey L, et al. Rituximab as first-line and maintenance therapy for indolent non-Hodgkin's lymphoma (NHL): long-term follow-up of a Minnie Pearl Cancer Research Network Phase II trial. Abstract 1496, updated in a poster presentation at the 45th Annual Meeting of the American Society of Hematology, December 6-9, 2003, San Diego, USA.
199. Itala M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. *Eur J Haematol* 2002;69:129-34.
200. Ghielmini M, Schmitz S-F, Cogliatti S, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard 4-weekly schedule. *Blood* 2004;103:4416-23.

201. Hochster HS, Weller E, Ryan T, et al. Results of E1496: A Phase II trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Abstract 6502, updated in an oral presentation at the Annual Meeting of the American Society of Oncology, June 5–8, 2004, New Orleans, USA.
202. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. *Cancer Biother Radiopharm* 1997;12:177–86.
203. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. *Semin Oncol* 2002;1(Suppl. 2):36–40.
204. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. *Anticancer Res* 2000;20:2961–6.
205. McLaughlin P, Hagemester F, Rodriguez M, et al. Safety of fludarabine, mitoxantrone and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. *Semin Oncol* 2000;27(Suppl. 12):37–41.
206. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphoma – results of a prospective randomized study *Blood*. *Blood* 2004;104:3064–71.
207. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. *J Clin Oncol* 1999;17:1962–3.
208. Grillo-Lo'pez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: ongoing and future clinical development. *Semin Oncol* 2002;29(Suppl. 2):105–12.
209. Rituxan_ prescribing information.
<http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf> (accessed July 2004).
210. Altman A. Acute tumor lysis syndrome. *Semin Oncol* 2001;28(Suppl. 2):3–8.
211. Sallan S. Management of acute tumor lysis syndrome. *Semin Oncol* 2001;28(Suppl. 2):9–12.
212. Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. *Am J Med* 1993;94:133–9.
213. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion related side effects and rapid blood tumor clearance. *J Clin Oncol* 1999;17:791–5.
214. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy. *J Clin Oncol* 1995;13:2431–8.
215. Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin's lymphoma and corrected with IVIG. *Ann Oncol* 2001;12:1493–4.

216. Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. *Br J Haematol* 2003;121:913–8.
217. Voog E, Morschhauser F, Solal-Ce'ligny P. Neutropenia in patients treated with rituximab. *N Engl J Med* 2003;348:2691–4.
218. Cairoli R, Grillo G, Tedeschini A, Avanzo G, Marengo P, Morra E. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. *Haematologica* 2004;89:361–3.
219. Battle M, Ribera JM, Oriol A, et al. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia [letter]. *Br J Haematol* 2002;118:1192–3.
220. Hernandez JA, Diloy R, Salat D, et al. Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab. *Haematologica* 2003;88:22.
221. Kami M, Hamaki T, Murashige N, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. *Hematol J* 2003;4:159–62.
222. Klepfish A, Stationer A, Shvidel L, et al. Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option. *Leuk Lymphoma* 2003;44:349–51.
223. D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDECC2B8 (rituximab). *Arthritis Rheum* 2001;44:1717–8.
224. Schmitz K, Brugger W, Weiss B, et al. Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab. *Br J Haematol* 1999;106:571–2.
225. Davis TA, Czerwinski DK, Levy R, et al. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. *Clin Cancer Res* 1999; 5:611–5.
226. Foran JM, Norton AJ, Micallef IN, Foran JM, Rohatiner AZ, Lister TA. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis. *Br J Haematol* 2001;114:881.
227. Jilani I, O'Brien S, Manshuri T, et al. Transient downregulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. *Blood* 2003;102:3514–20.
228. Tetreault S, Abler SL, Robbins B, et al. Peripheral T-cell lymphoma after anti-CD20 antibody therapy [published erratum appears in *J Clin Oncol* 1998;16:2001]. *J Clin Oncol* 1998;16:1635–7.
229. Maloney DG, Davis T, Levy R. Peripheral T-cell lymphoma after anti-CD20 antibody therapy. *J Clin Oncol* 1998;16:1636–7.
230. Lowndes S, Darby A, Mead G. Stevens–Johnson syndrome after treatment with rituximab. *Ann Oncol* 2002;13:1948–50.
231. Heizmann M, Itin P, Wernli N, Borradori L, Bargetzi MJ. Successful treatment of paraneoplastic pemphigus in fol- 472 E. Kimby licular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL. *Am J Hematol* 2001;66:142–4.

232. Kanelli S, Ansell SM, Habermann T, Inwards DI, Tuinstra N, Witzig TE. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. *Leuk Lymphoma* 2001;42:1329-37.
233. Burton C, Kaczmarek R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. *N Engl J Med* 2003;348:2690-1.
234. Alexandrescu DT, Ditcher JP, O'Boyle K, Albumet M, Oiseth PH, Wiernek PH. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. *Leuk Lymphoma* 2004;45:2321-5.
235. Hainsworth JD, Litchy S, Lamb MR, Rodriguez GI, Scroggin FA, Greco FA. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial. *Clin Lymphoma* 2003;4:36-42.
236. Benyunes MC, Multani PS, Saunders A. Interstitial pneumonitis related to rituximab therapy [Response to Burton et al. 2003]. *N Engl J Med* 2003;348:2691.
237. Hale G, Dyer MJ, Clark MR et al. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. *Lancet* 1988; 2: 1394-1399.
238. Ginaldi L, De Martinis M, Matutes E et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vitro therapeutic responses to Campath-1H. *Leukemia Research* 1998; 22: 1185-1191.
239. Iannello A, Ahmad A. Role of antibody-dependent cell mediated cytotoxicity in the efficacy of therapeutic anticancer monoclonal antibodies. *Cancer Metastasis Rev.* 2005;24:487-499.
240. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. *J Immunother.* 1994; 15:42-52.
241. Mirick GR, Bradt BM, Denardo SJ, Denardo GL. A review of human anti-globulin antibody (HAGA, HAMA, HACA, HAHA) responses to monoclonal antibodies. Not four letter words. *QJ Nucl Med Mol Imaging.* 2004;48:251-257.
242. Campath (alemtuzumab). Available at: <http://www.rxlist.com>. Accessed June 18, 2007. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1 H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). *Blood.* 2002;100:768-773.
243. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. *Blood.* 2004;104:948-955.
244. Rai KR, Stephenson J, eds. *Campath-1H: Emerging Frontline Therapy in Chronic Lymphocytic Leukemia*. New York, NY: Parthenon Publishing; 2001.
245. Salisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CD52 antigen expression in non-Hodgkin's lymphomas. *J Clin Pathol.* 1994;47:313-317.
246. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal

- antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. *Leukemia*. 2004; 18:484-490.
247. Rawstron AC, Kennedy B, Moreton P, et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. *Blood*. 2004; 103:2027-2031.
248. Keating M, Coutre S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. *Clin Lymphoma*. 2004;4:220-227.
249. Osterborg A, Dyer MJ, Bunjes D, et al, for the European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. *J Clin Oncol*. 1997;15:1567-1574.
250. Alemtuzumab: Fatal progressive multifocal leuko encephalopathy (first report) in an elderly patient: Case report. *Reactions*. 2006;1:6-6(1).
251. Laurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: Incidence and treatment with oral ganciclovir. *Haematologica*. 2004;89:1248- 1252.
252. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. *Leukemia*. 2005;19:1207-1210.
253. O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. *Clin Lymphoma Myeloma*. 2006;7:125-130.
254. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. *Br J Haematol*. 2006;132:3-12.
255. Grillo-Lopez AJ, Dallarie BK, McClure A, et al Monoclonal antibodies: a new era in the treatment of non-Hodgkin's lymphoma. *Curr Pharm Biotechnol*, 2: 301-11, 2001.
256. Cesano A, Gayko U, Brannan C, et al Differential expression of CD22 by indolent and aggressive NHLs: implications for targeted immunotherapy. *Blood*, 100: 350a 2002.
257. Sato S, Tuscano JM, Inaoki M, Tedder TF. CD.22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. *Semin Immunol*, 10: 287-97, 1998.
258. Otipoby KL, Andersson KB, Draves KE, et al CD22 regulates thymus-independent responses and the lifespan of B cells. *Nature (Lond)*, 384: 634-7, 1996.
259. Sato S, Miller AS, Inaoki M, et al CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. *Immunity*, 5: 551-62, 1996.
260. Stein R, Belisle E, Hansen HJ, Goldenberg DM. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. *Cancer Immunol Immunother*, 37: 293-8, 1993.
261. Carnahan J, Wang P, Kendal IR. Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. *Clin Cancer Res*, 9: 3982S-90S, 2003.

262. Linden O, Tennevall J, Hindorf C, et al Radioimmunotherapy using ¹³¹I-labelled anti-CD22 monoclonal antibody (LL2) in patients with previously-treated B-cell lymphomas. *Clin Cancer Res*, 5(Suppl 10): 3287s-91s, 1999.
263. Gada P, Hernandez-Ilizaliturri FJ, Repasky EA, Czuczman MS. Epratuzumab's predominant antitumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibody-dependent cellular cytotoxicity (ADCC). *Blood*, 100: 353a 2002.
264. Leonard JP, Coleman M, Matthews JC, et al Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. *Proc Am Soc Clin Oncol*, 21: 266a 2002.
265. Briddell R, Kern B, Stoney G, et al The effect of epratuzumab on peripheral blood B-cell levels in normal, male cynomolgus monkeys. *Blood*, 100: 576a 2002.
266. Savage KJ. Aggressive Peripheral T-Cell lymphomas (specified and unspecified types). *American Society of Haematology Education Programme Book 2005*:267-77.
267. Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, et al. The Anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. *Cancer Research* 2002;62:3736-42.
268. Hubinger G, Muller E, Scheffrahn I, Schneider C, Hildt E, Singer BB, et al. CD30-mediated cell cycle arrest associated with induced expression of p21(CIP1/WAF1) in the anaplastic large cell lymphoma cell line Karpas 299. *Oncogene* 2001;20:590-8.
269. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Stak O, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. *Blood* 2003;102:3737-42.
270. Ansell SM, Byrd JC, Horwitz SM, Borchman P, Engert A, Strair R, et al. Phase I/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma (abstract). *Blood* 2004;104:2636a.
271. Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, et al. Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines. *Immunother.* 2004;27:347-53.
272. Boll B, Hansen H, Heuck F, Reiners K, Borchmann P, Rothe A, et al. The fully human anti-CD30 antibody 5F11 activates NF- κ B and sensitizes lymphoma cells to bortezomib-induced apoptosis. *Blood* 2005;106:1839-42.
273. Valbuena JR, Atwell C, Giorgakis GV, Younes A, Medeiros LJ, Rassidakis GZ. SGN-30, a novel chimeric anti-CD30 antibody induces cell-cycle arrest and apoptosis in ALK+ anaplastic large cell lymphoma. *Prog AM Assoc Cancer Res* 2005;46 Abs 449.
274. Cervený CG, Law C-L, McCormick RS, Lenox JS, Hamblett KJ, Yamane AK, et al. Signaling via the anti-CD30mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. *Leukemia* 2005;19 1648-1655
275. McLaughlin P, Rodriguez MA, Hagemeister FB, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs sequential use of

- FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. *Proc Am Soc Clin Oncol* 2003;22:564.
276. Solal-Celigny P, Imrie K, Belch A, et al. MabThera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): confirmed efficacy with longer follow-up. *Blood* 2005;106:106a.
 277. Herold M, Pasold R, Srock S, et al. Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma: results of a phase III study (OSHO39). *Ann Oncol* 2005;16(Suppl 5):v51ev52.
 278. Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts). *J Clin Oncol* 2006; 24(18S):424s.
 279. Imrie K, Belch A, Pettengell R, et al. CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: impact of baseline prognostic factors. *Ann Oncol* 2005;16(Suppl 5):v109ev110.
 280. Cunningham D, Aultman R, Jost F, Marcus R. Q-TWiST analysis of rituximab plus CVP versus CVP alone as first-line treatment for advanced follicular lymphoma. *Haematologica* 2005;90(S2):274.
 281. Hiddemann W, Dreyling MH, Fortspointner R, et al. Combined immunochemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *Blood* 2003;102:104a.
 282. Buske C, Hoster E, Dreyling M, et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with respect to treatment outcome. *Blood* 2006; 108:1504-1508.
 283. Salles GA, Foussard C, Mounier N, et al. Rituximab added to aIFNCHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELAGOELAMS FL-2000 randomized trial in 359 patients. *Blood* 2004; 104:49a.
 284. Herold M, Pasold R, Srock S, et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). *Blood* 2004;104:169a.
 285. Rivas-Vera S, Baez E, Sobrevilla-Calvo P, Baltazar S, Tripp F, Vela J, et al. Is first line single agent rituximab the best treatment for indolent non-Hodgkin's lymphoma? Update of a multicentric study comparing rituximab vs. CNOP vs. rituximab plus CNOP [abstract]. *Blood* 2005;106(11).
 286. Herold M, Pasold R, Srock S, Naser S, Niederwieser D, Neubauer A, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL) [abstract]. *Blood* 2004;104(11).

287. Foussard C, Mounier N, Van Hoof A, Delwail V, Casasnovas O, Deconinck E, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts) [abstract]. *J Clin Oncol* (ASCO Annual Meeting Proceedings) 2006;24(18 Suppl.).
288. Buske C, Dreyling MH, Eimermacher H, Boeck H-P, Pfreundschuh M, Metzner B, et al. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment failure in first line treatment of patients with lymphoplasmacytoid/ic immunocytoma (LP-IC) – results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) [abstract]. *Blood* 2004;104(11).
289. Lenz G, Dreyling M, Hoster E, Woßmann, Duhrsen U, Metzner B, et al. Immunotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol* 2005;23(9):1984–92.
290. Van Oers MHJ, Van Glabbeke M, Teodorovic I, Rozewicz C, Klasa RE, Marcus RE, et al. EORTC Lymphoma Group. Chimeric anti- CD20 monoclonal antibody (rituximab;Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: Final analysis of a phase III randomized Intergroup clinical trial [abstract]. *Blood* 2005;106(11).
291. Hochster HS, Weller E, Gascoyne R, Ryan T, Habermann TM, Gordon LI, et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B [abstract]. *Blood* 2005;106(11).
292. Ghielmini M, Schmitz S-FH, Cogliatti S, Bertoni F, Waltzer U, Fey MR, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). *J Clin Oncol* 2005;23(4):705–11.
293. Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma – a randomized phase II trial of the Minnie Pearl Cancer Research Network. *J Clin Oncol* 2005;23(6):1088–95.
294. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium- 90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. *J Clin Oncol* 2002;20(10):2453–63.
295. Schulz H, Skoetz N, Bohlius J, Trelle S, Kober T, Greb A, et al. Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis [abstract]. *Blood* 2005;106(11).

296. Hagenbeek A, Van Glabbeke M, Teodorovic I, et al. The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial. *Ann Oncol* 2005;16(Suppl 5):v52.
297. Dreyling M, Forstpointner R, Ludwig W, et al. The addition of rituximab to a fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *Ann Oncol* 2005;16(Suppl 5):v110.
298. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. *Blood* 2001;97:101-106.
299. Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. *J Clin Oncol* 2005;23:1103e.
300. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. *Blood* 2006;108(10):3295-3301.
301. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low4 Lister TA, Cullen MH, Beard ME, et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favorable histological type. *Br Med J* 1978;1:533-537.
302. Dreyling M, Forstpointner R, Ludwig W, et al. The addition of rituximab to a fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma: follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *Ann Oncol* 2005;16(Suppl 5): v110.
303. Dreyling M, Forstpointner R, Gramatzki M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). *J Clin Oncol* 2006; 24(18S):422s.
304. Lemieux B, Bouafia F, Thieblemont C, et al. Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. *Hematol J* 2004;5:467-471.
305. Weide R, Heymanns J, Koeppler H, et al. Bendamustine/mitoxantrone/rituximab (BMR): a very effective and well tolerated immuno-chemotherapy for relapsed and refractory

- indolent lymphomas e high response rate in patients pretreated with rituximab e results of a multicentre phase-II-study of the German Low Grade Lymphoma Study Group (GLSG). *Proc Am Soc Clin Oncol* 2005;23:589s.
306. Feugier P, Van Hoof A, Sebban C et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 2005;23:4117-26.
 307. Habermann TM, Weller EA, Morrison VA et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. *J Clin Oncol* 2006;24:3121-7.
 308. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. *J Clin Oncol* 2005;23:5027-33.
 309. Pfreundschuh M, Trumper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. *Lancet Oncol* 2006;7:379-91.
 310. Pfreundschuh M, Trumper L, Kloess M et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. *Blood* 2004;104:626-33.
 311. National Comprehensive Cancer Network. Non-Hodgkin's lymphomas: the national comprehensive cancer network clinical practice guidelines in oncology, version 1.2007; March 2, 2007. <<http://www.nccn.org>> [accessed 14.05.07].
 312. Pfreundschuh M, Schubert J, Ziepert M et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). *Lancet Oncol* 2008;9:105-16.
 313. Schubert J, Reiser M, Wenger M et al. Bi-weekly dosing preserves the efficacy of rituximab in elderly patients with poor-prognosis DLBCL: results from the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study group (DSHNHL). *J Clin Oncol* 2006;24
 314. Poeschel V, Nickelsen M, Hanel M et al. Dose-dense rituximab in combination with biweekly CHOP-14 for elderly patients with diffuse large B-cell lymphoma(DLBCL): results of a phase-I/II and pharmacokinetic study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). *Blood* 2006;108:774a.
 315. Reiser M, Wenger M, Nickenig C, Peter N, Metzner B, Pfreundschuh M. Serum levels and pharmacokinetic of rituximab in bi-weekly R-CHOP in elderly patients with DLBCL treated in the RICOVER-60 trial. *J Clin Oncol* 2006;24(18S)
 316. Sonneveld P, van Putten W, Biesma B et al. Phase III trial of 2-weekly CHOP with rituximab for aggressive B-cell non- Hodgkin's lymphoma in elderly patients. *Blood* 2006;108 .
 317. Delarue R, Mournier N, Haioun C et al. Safety of prophylactic use of darbepoetin alfa in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP 14 or RCHOP21: preliminary results of the LNH03-6B randomized GELA study. *Blood* 2006;108.

318. UK Clinical Research Network. A phase III multicentre randomised clinical trial comparing rituximab with CHOP given every 14 days and rituximab with CHOP given every 21 days for the treatment of patients with newly diagnosed diffuse large B cell non-Hodgkin's lymphoma. UKCRN ID 1437. <<http://pfsearch.ukcrn.org.uk/StudyDetail.aspx?TopicID=1&StudyID=1437>> [accessed 18.06.07].
319. Bosly A, Bron D, Van Hoof A et al for the Lymphoma Dose Project: a National Study. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. *Ann Hematol* 2008;87:277–83.
320. Lee KW, Kim DY, Yun T et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. *Cancer* 2003;98:2651–6.
321. Lepage E, Gisselbrecht C, Haioun C et al for the Groupe d'Etude des Lymphomes de l'Adulte. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. *Ann Oncol* 1993;4:651–6.
322. Epelbaum R, Faraggi D, Ben-Arie Y et al. Survival of diffuse large cell lymphoma: a multivariate analysis including dose intensity variables. *Cancer* 1990;66:1124–9.
323. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. *J Clin Oncol* 1990;8:963–77.
324. Lo'pez A, Alonso JD, Go'mez-Codina J et al. Febrile neutropenia in lymphoma patients is associated with substantial resource use and healthcare costs in clinical practice in Spain. *Blood* 2006;108 [Abstract 5512].
325. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. *Support Care Cancer* 2008 [Epub ahead of print].
326. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. *Eur J Cancer* 2006;42:2433–53.
327. Wolf M, Bentley M, Marlton P et al. Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma. *Leuk Lymphoma* 2006;47:2344–50.
328. Mey UJ, Maier A, Schmidt-Wolf IG et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. *Support Care Cancer* 2007;15:877–84.
329. Brusamolino E, Rusconi C, Montalbetti L et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. *Haematologica* 2006;91:496–502.
330. Moore TD, Patel T, Segal ML et al. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkin's lymphoma. In: Presented at the 2003 annual meeting of the American Society of Hematology, December 7, 2003, San Diego, CA [Poster 2365].

331. Smith TJC, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. *J Clin Oncol* 2006;24:3187–205.
332. National Comprehensive Cancer Network. Myeloid growth factors: the national comprehensive cancer network clinical practice guidelines in oncology, version 1.2007; December 8, 2006. <<http://www.nccn.org>> [accessed 14.05.07].
333. Ries LAG, Eisner MP, Kosary CL et al. SEER cancer statistics review, 1973–1997. Bethesda (MD): National Cancer Institute; 2000.
334. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. *J Clin Oncol* 2004;22:4302–11.
335. Morrison VA, Picozzi V, Scott S et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. *Clin Lymphoma* 2001;2:47–56.
336. Repetto L, Biganzoli L, Koehne CH et al. EORTC cancer in the elderly task force guidelines for the use of colony stimulating factors in elderly patients with cancer. *Eur J Cancer* 2003;39:2264–72.
337. Morrison VA, Weller EA, Habermann TM et al. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP: an intergroup experience (CALGB 9793, ECOG-SWOG 4494). *Blood* 2004;104 [Abstract 3309].
338. Chen-Hardee S, Chrischilles EA, Voelker MD et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). *Cancer Cause Contr* 2006;17:647–54.
339. Balducci L, Al-Halawani H, Charu V et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. *Oncologist* 2007;12:1416–24.
340. Leeumann A, Lifely MR, Schneider P et al. Primary Structure of CD52. *Journal of Biological Chemistry* 1995; 270: 6088-6099.
341. Gilleece MH & Dexter TM. Effects of CAMPATH-1H antibody on human haemopoietic progenitors in vitro. *Blood* 1993; 82: 807-812.
342. Heit W, Bunjes D, Wiesneth M et al. Ex vivo T-cell depletion with the monoclonal antibody Campath- 1H plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation. *British Journal of Haematology* 1986; 64: 479-486.
343. Dyer MJ, Hale G, Hayhoe FG et al. Effects of Campath 1-H antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. *Blood* 1989; 73: 1431-1439.
344. Rowan W, Tite J, Topley P et al. Cross-linking of the Campath 1-H antigen (CD52) mediates growth inhibition in human B- and T-lymphocytes cell lines and subsequent emergence of CD52-deficient cells. *Immunology* 1998; 95: 427-436.
345. Matutes E, Brito-Babapulle V, Swansbury J et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukaemia. *Blood* 1991; 78: 3269-3274.
346. Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with Campath-1H. *Blood* 2001; 98(6): 1721-1726.

347. Keating MJ, Cazin B, Coutre S et al. Campath-1H Treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. *Journal of Clinical Oncology* 2002; 20: 205-213.
348. Dearden C, Matutes E, Cazin B et al. Very high response rates in previously untreated T-cell prolymphocytic leukaemia patients receiving alemtuzumab (Campath-1H) therapy. *Blood* 2003; 102 [Abstract 2378].
349. Hopfinger G, Busch R, Eichorst B et al. T-PLL-1 Protocol of the German CLL Study Group (GCLLSG) e a prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL. *Blood* 2005; 106 [Abstract 2130].
350. Mahieux R & Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. *Reviews in Clinical and Experimental Hematology* 2003; 7: 336-361.
351. Iwanaga R, Ohtani K, Hayashi T et al. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. *Oncogene* 2001; 20: 2055-2067.
352. Kamada N, Sakurai M, Miyamoto K et al. Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report. *Cancer Research* 1992; 52: 1481-1493.
353. Matutes E, Taylor GP, Cavenagh J et al. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. *British Journal of Hematology* 2001; 113: 779-784.
354. Hermine O, Dombret H, Poupon J et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. *The Hematology Journal* 2004; 5: 130-134.
355. Ishida T, Lida S, Akatsua Y et al. CCR4: chemokine receptor as a novel molecular target for immunotherapy in adult T-cell leukemia/lymphoma (ATLL). *Blood* 2003; 102 [Abstract 3348].
356. Zhang Z, Zhang M, Goldman CK et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Alemtuzumab-1H. *Cancer Research* 2003; 63: 6453-6457.
357. Mone A, Puhalla S, Whitman S et al. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN- α -refractory adult T-cell leukaemia. *Blood* 2005; 106(10): 3380-3382.
358. Ravandi F & Faderl S. Complete response in a patient with adult T-cell leukaemia (ATL) treated with combination of alemtuzumab and pentostatin. *Leukemia Research* 2006; 30(1): 103-105.
359. Kim YH & Hoppe RT. Mycosis Fungoides and the Sezary syndrome. *Seminars in Oncology* 1999; 26: 276-289.
360. Scarisbrick JJ, Woolford AJ, Russell-Jones R et al. Allelotyping in mycosis fungoides and Sezary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. *The Journal of Investigative Dermatology* 2001; 117: 663-670.
361. Kuzel TM, Roenigk Jr. HH, Samuelson E et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. *Journal of Clinical Oncology* 1995; 13: 257-263.
362. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T-cell lymphoma:

- multinational phase II-III trial results. *Journal of Clinical Oncology* 2001; 19: 2456-2471.
363. Wollina U, Dummer R, Brockmeyer NH et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. *Cancer* 2003; 98: 993-1001.
364. Dearden C, Matutes E & Catovsky D. Pentostatin treatment of cutaneous T-cell lymphoma. *Oncology (Huntingt)* 2000; 14: 37-40.
365. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. *Blood* 1996; 87: 906-911.
366. Foss FM, Ihde DC, Linnoila IR et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. *Journal of Clinical Oncology* 1994; 12: 2051-2059.
367. Saleh MN, LeMaistre CF, Kuzel TM et al. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. *Journal of the American Academy of Dermatology* 1998; 39: 63-73.
368. Obitz E, Kim YH, Iversen L et al. HuMax-CD4, a fully human monoclonal antibody: early results of an ongoing phase II trial in cutaneous T cell lymphoma (CTCL). *Blood* 2003; 102 [Abstract 2383].
369. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. *European Study Group of Campath-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology* 1998; 16: 3257-3263.
370. Lundin J, Hagberg H, Repp R et al. Phase 2 study of alemtuzumab (anti-Cd52 monoclonal antibody) in patients with advanced mycosis Fungoides/Sezary syndrome. *Blood* 2003; 101(11): 4267-4272.
371. Foukaneli T, Marsh J, Pettengell R et al. Sezary syndrome responds to treatment with Alemtuzumab-1H. *Blood* 2001; 98 [Abstract 556].
372. Capalbo S, Delia M, Dargenio M et al. Mycosis fungoides/Sezary syndrome: a report of three cases treated with Alemtuzumab-1H as salvage treatment. *Medical Oncology* 2003; 20: 389-396
373. Kennedy GA, Seymour JF, Wolf M et al. Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. *European Journal of Haematology* 2003; 71: 250-256.
374. Lenihan DJ, Alencar AJ, Yang D et al. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/ Sezary syndrome. *Blood* 2004; 104(3): 655-658.
375. Lundin J, Kennedy B, Dearden C et al. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Se'zary syndrome. *Blood* 2005; 105(10): 4148-4149.
376. Weder P, Anliker M, Itin P et al. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab. *Dermatology* 2004; 208: 281-283.
377. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. *Blood* 2004; 103(7): 2474-2479.
378. Zettl A, Rudiger T, Konrad MA et al. Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma

- delineates novel recurrent chromosomal alterations. *The American Journal of Pathology* 2004; 164: 1837-1848.
379. Dutcher JP. The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas. *Leukemia Research* 2003; 27: 467-469.
380. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. *Blood* 2004; 103(8): 2920-2924.
381. Zinzani PL, Alinari L, Tani M et al. Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. *Haematologica* 2005; 90(5): 702-703.
382. Gallamini A, Zaja F, Gargantini L et al. CHOP chemotherapy plus Alemtuzumab-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL). *Annals of Oncology* 2005; 16 [Abstract 321].
383. Weidmann E, Hess G, Krause SW et al. Alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin; An effective first-line treatment in peripheral T-cell lymphomas. *Annals of Oncology* 2005; 16 [Abstract 232].
384. Wulf GG, Hasenkamp J, Jung W et al. Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. *Bone Marrow Transplantation* 2005; 36(3): 271-273.
385. Kahl C, Leithauser M, Wolff D et al. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation. *Annals of Hematology* 2002; 81: 646-650.
386. Hekman A, Honselaar A, Vuist WMJ, et al Initial experience with treatment of human B-cell lymphoma with anti-CD19 monoclonal antibody. *Cancer Immunol Immunother*, 32: 364-72, 1991.
387. Nadler LM, Stashenko P, Hardy R, Schlossman SF. A monoclonal antibody defining a lymphoma-associated antigen in man. *J Immunol*, 125: 570-7, 1980.
388. Hsu FJ, Kwak L, Campbell M, et al Clinical trials of idiotype-specific vaccine in B-cell lymphomas. *Ann N Y Acad Sci*, 690: 385-7, 1993.
389. Press OW, Appelbaum F, Ledbetter JA, et al Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. *Blood*, 69: 584-91, 1987.
390. Amlot PL, Stone MJ, Cunningham D, et al A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. *Blood*, 82: 2624-33, 1993.
391. Kreitman RJ, Hansen HJ, Jones AL, et al Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice. *Cancer Res*, 53: 819-25, 1993.
392. Newton DL, Hansen HJ, Liu H, et al Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents. *Crit Rev Oncol Hematol*, 39: 78-86, 2001.
393. Leonard JP, Coleman M, Matthews JC, et al Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. *J Clin Oncol*, 21: 3051-9, 2003.

394. Falini B, Bolognesi A, Flenghi L, et al. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin. *Lancet* 1992;339:1195-6.
395. Schwab U, Stein H, Gerdes J, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. *Nature* 1982;299: 65-7.
396. Horie R, Watanabe T. CD30: expression and function in health and disease. *Semin Immunol* 1998;10:457-70.
397. Chiarle R, Podda A, Prolla G, et al. CD30 overexpression enhances negative selection in the thymus and mediates programmed cell death via a Bcl-2-sensitive pathway. *J Immunol* 1999;163:194-205.
398. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. *Blood* 2000;96:4307-12.
399. Horie R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. *Int J Hematol* 2003;77:37-47.
400. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. *Curr Opin Pharmacol* 2004;4: 355-9.
401. Bartlett NL, Younes A, Carabasi MA, et al. Phase I study of SGN-30, a chimeric monoclonal antibody (mAb) in patients with refractory or recurrent CD30+ hematologic malignancies. *Blood* 2002;100 [abstract 1403].
402. Carabasi MA, Bartlett NL, Younes A, et al. Pharmacokinetics, safety, and tolerability of SGN-30, a chimeric monoclonal antibody (mAb), administered as a single dose to patients with CD30+ hematologic malignancies. *Proc Am Soc Clin Oncol* 2003;22 [abstract 722].
403. Bartlett NL, Bernstein SH, Leonard JP, et al. Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies. *Blood* 2003;102 [abstract 2390].
404. Leonard JP, Younes A, Rosenblatt JD, et al. Targeting CD30 as therapy for Hodgkin's disease. Phase II results with the monoclonal antibody SGN-30. *ASCO Annu Meet Proc* 2005;23 [abstract 2553].
405. Schnell R, Borchmann P. SGN-30 (Seattle genetics). *Curr Opin Mol Ther* 2006;8:164-72.
406. Schnell R, Staak O, Borchmann P, et al. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. *Clin Cancer Res* 2002;8:1779-86.
407. Hu XF, Xing PX. MDX-060. Medarex. *Curr Opin Invest Drugs* 2005;6:1266-71.
408. Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. *J Clin Oncol* 2007;25: 2764-9.
409. Hammond PW, Vafa O, Jacinto J, et al. A humanized anti-CD30 monoclonal antibody, XmAbTM2513, with enhanced in vitro potency against CD30-positive lymphomas mediated by high affinity Fc receptor binding. *Blood* 2005;106 [abstract 1470].
410. Duvic M, Kunishige J, Kim Y, Reddy S, Forero A, Pinter Brown L, et al. Phase II preliminary results suggest SGN30 (anti-CD30 monoclonal

- antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma. *J. Invest Dermatol* 2006;126(S4)
411. Pizzolo G, Vinante F, Chilosi M, et al. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage. *Br J Haematol* 1990;75: 282-4.
 412. Schnell R, Vitetta E, Schindler J, et al. Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin. *Leukemia* 2000;14:129-35.
 413. Falini B, Pasqualucci L, Flenghi L. Anti-CD30 immunotoxins: experimental and clinical studies. In: Proceedings of the fourth international symposium on immunotoxins. 1995 [Abstract 160]
 414. Hamblett KJ, Barton J, Cervený CG, et al. SGN-35, an anti-CD30 antibody-drug conjugate, exhibits potent antitumor activity for the treatment of CD30+ malignancies. *Blood* 2005;106 [abstract 610].
 415. Francisco JA, Cervený CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. *Blood* 2003;102:1458-65.
 416. Heuser C, Gohlke S, Matthies A, et al. Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytotoxicity of Hodgkin's lymphoma derived tumor cells. *Int J Cancer* 2004;110:386-94.
 417. Heuser C, Diehl V, Abken H, Hombach A. Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. *Int J Cancer* 2003;106:545-52.
 418. Klimka A, Barth S, Matthey B, et al. An anti-CD30 single-chain Fv selected by phage display and fused to pseudomonas exotoxin A (Ki-4(scFv)-ETA') is a potent immunotoxin against a Hodgkin-derived cell line. *Br J Cancer* 1999;80:1214-22.
 419. Barth S, Huhn M, Matthey B, et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. *Blood* 2000;95:3909-14.
 420. Nagata S, Onda M, Numata Y, et al. Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments. *Clin Cancer Res* 2002;8:2345-55.
 421. Hartmann F, Renner C, Jung W, et al. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 Bispecific antibody. *Blood* 1997;89:2042-7.
 422. Hartmann F, Renner C, Jung W, et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. *Clin Cancer Res* 2001;7:1873-81.
 423. Borchmann P, Schnell R, Fuss I, et al. Phase I trial of the novel bispecific molecule H22×Ki-4 in patients with refractory Hodgkin lymphoma. *Blood* 2002;100:3101-7.
 424. Sundarapandian K, Keler T, Behnke D, et al. Bispecific antibody mediated destruction of Hodgkin's lymphoma cells. *J Immunol Methods* 2001;248:113-23.

425. Schnell R, Dietlein M, Staak JO, et al. Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. *J Clin Oncol* 2005;23:4669-78.
426. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. *Blood* 2000;95:1443-50.
427. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. *J Exp Med* 1996;184:1495-505.
428. Rehwald U, Schulz H, Reiser M, et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin lymphoma study group. *Blood* 2003;101:420-4.
429. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte predominant Hodgkin disease: results of a phase 2 trial. *Blood* 2003;101:4285-9.
430. Younes A, McLaughlin P, Goy A, et al. Rituximab plus ABVD therapy for newly diagnosed patients with classical Hodgkin's disease: a novel combination program targeting the cancer cells and the microenvironment. *Blood* 2003;102 [Abstract 83].
431. Younes A, Romaguera J, Hagemester F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. *Cancer* 2003;98:310-4.
432. Younes A, McLaughlin P, Fayad LE, et al. Six weekly doses of rituximab plus ABVD for newly diagnosed patients with classical Hodgkin lymphoma: depletion of reactive B cells from the microenvironment by rituximab. *Blood* 2005;106 [Abstract 1499].
433. Younes A, Pro B, Goy A, Fayad L, Romaguera J. Gemcitabine plus rituximab therapy of patients with relapsed and refractory classical Hodgkin's disease: depletion of benign B cells from HD microenvironment by rituximab may enhance the activity of gemcitabine. *Blood* 2003;102 [Abstract 1500].
434. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. *N Engl J Med* 1998;339:1506-14.
435. Jones RJ, Lin L, Gocke C, et al. Clonotypic B cells circulate in Hodgkin's lymphoma (HL). *Blood* 2006;108 [Abstract 470].
436. J. Cuzick, T. Powles, U. Veronesi, J. Forbes, R. Edwards, S. Ashley, P. Boyle, Overview of the main outcomes in breast-cancer prevention trials, *Lancet* 361 (2003) 296-300.
437. Y. Noguchi, A. Jungbluth, E.C. Richards, L.J. Old, Effect of interleukin 12 on tumor induction by 3-methylcholanthrene, *Proc. Natl. Acad. Sci. U. S. A.* 93 (1996) 11798-11801.
438. P.L. Lollini, F. Cavallo, P. Nanni, G. Forni, Vaccines for tumour prevention, *Nat. Rev., Cancer* 6 (2006) 204-216.
439. T. Iinuma, S. Homma, T. Noda, D. Kufe, T. Ohno, G. Toda, Prevention of gastrointestinal tumors based on adenomatous polyposis coli

- gene mutation by dendritic cell vaccine, *J. Clin. Invest.* 113 (2004) 1307–1317.
440. E. Quaglino, S. Rolla, M. Iezzi, M. Spadaro, P. Musiani, C. De Giovanni, P.L. Lollini, S. Lanzardo, G. Forni, R. Sanges, S. Crispi, P. De Luca, R. Calogero, F. Cavallo, Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions, *J. Clin. Invest.* 113 (2004) 709–717.
441. C. Mao, L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, D.J. Wiley, F.B. Alvarez, O.M. Bautista, K.U. Jansen, E. Barr, Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial, *Obstet. Gynecol.* 107 (2006) 18–27.
442. Future II Study group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions, *N. Engl. J. Med.* 356 (2007) 1915–27.
443. I. Melero, S. Hervas-Stubbs, M. Glennie, D.M. Pardoll, L. Chen, Immuno stimulatory monoclonal antibodies for cancer therapy, *Nat. Rev., Cancer* 7 (2007) 95–106.
444. R.A. Morgan, M.E. Dudley, J.R. Wunderlich, M.S. Hughes, J.C. Yang, R.M. Sherry, R.E. Royal, S.L. Topalian, U.S. Kammula, N.P. Restifo, Z. Zheng, A. Nahvi, C.R. de Vries, L.J. Rogers-Freezer, S.A. Mavroukakis, S.A. Rosenberg, Cancer regression in patients after transfer of genetically engineered lymphocytes, *Science* 314 (2006) 126–129.
445. J. Banchereau, A.K. Palucka, Dendritic cells as therapeutic vaccines against cancer, *Nat. Rev., Immunol.* 5 (2005) 296–306.
446. A. Hoos, G. Parmiani, K. Hege, M. Sznol, H. Loibner, A. Eggermont, W. Urba, B. Blumenstein, N. Sacks, U. Keilholz, G. Nichol, A clinical development paradigm for cancer vaccines and related biologics, *J. Immunother.* 30 (1997) (2007) 1–15.
447. T. Seya, T. Akazawa, J. Uehori, M. Matsumoto, I. Azuma, K. Toyoshima, Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer, *Anticancer Res.* 23 (2003) 4369–4376.
448. L. Chapatte, M. Ayyoub, S. Morel, A.L. Peitrequin, N. Levy, C. Servis, B.J. Van den Eynde, D. Valmori, F. Levy, Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses, *Cancer Res.* 66 (2006) 5461–5468.
449. J. N. Vigneron, V. Stroobant, J. Chapiro, A. Ooms, G. Degiovanni, S. Morel, P. van der Bruggen, T. Boon, B.J. Van den Eynde, An antigenic peptide produced by peptide splicing in the proteasome, *Science* 304 (2004) 587–590.
450. J.W. Fay, A.K. Palucka, S. Paczesny, M. Dhodapkar, D.A. Johnston, S. Burkeholder, H. Ueno, J. Banchereau, Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells, *Cancer Immunol. Immunother.* 55 (2006) 1209–1218.
451. Z. Yu, M.R. Theoret, C.E. Touloukian, D.R. Surman, S.C. Garman, L. Feigenbaum, T.K. Baxter, B.M. Baker, N.P. Restifo, Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance, *J. Clin. Invest.* 114 (2004) 551–559.

452. J.M. Blander, R. Medzhitov, Toll-dependent selection of microbial antigens for presentation by dendritic cells, *Nature* 440 (2006) 808–812.
453. D. Accapezzato, V. Visco, V. Francavilla, C. Molette, T. Donato, M. Paroli, M.U. Mondelli, M. Doria, M.R. Torrisi, V. Barnaba, Chloroquine enhances human CD8⁺ T cell responses against soluble antigens *in vivo*, *J. Exp. Med.* 202 (2005) 817–828.
454. E. Gilboa, The promise of cancer vaccines, *Nat. Rev., Cancer* 4 (2004) 401–411.
455. D. Dudziak, A.O. Kamphorst, G.F. Heidkamp, V.R. Buchholz, C. Trumpfheller, S. Yamazaki, C. Cheong, K. Liu, H.W. Lee, C.G. Park, R.M. Steinman, M.C. Nussenzweig, Differential antigen processing by dendritic cell subsets *in vivo*, *Science* 315 (2007) 107–111.
456. G. Dontu, W.M. Abdallah, J.M. Foley, K.W. Jackson, M.F. Clarke, M.J. Kawamura, M.S. Wicha, *In vitro* propagation and transcriptional profiling of human mammary stem/progenitor cells, *Genes Dev.* 17 (2003) 1253–1270.
457. S. Pellegatta, P.L. Poliani, D. Corno, F. Menghi, F. Ghielmetti, B. Suarez-Merino, V. Caldera, S. Nava, M. Ravanini, F. Facchetti, M.G. Bruzzone, G. Finocchiaro, Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas, *Cancer Res.* 66 (2006) 10247–10252.
458. G. Kraal, J.N. Samsom, R.E. Mebius, The importance of regional lymph nodes for mucosal tolerance, *Immunol. Rev.* 213 (2006) 119–130.
459. F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M.P. Colombo, G. Dougan, M. Rescigno, Cancer immunotherapy based on killing of salmonella-infected tumor cells, *Cancer Res.* 65 (2005) 3920–3927.
460. M.H. den Brok, R.P. Suttmuller, S. Nierkens, E.J. Bennink, L.W. Toonen, C.G. Figdor, T.J. Ruers, G.J. Adema, Synergy between *in situ* cryoablation and TLR9 stimulation results in a highly effective *in vivo* dendritic cell vaccine, *Cancer Res.* 66 (2006) 7285–7292.
461. J.R. Mora, G. Cheng, D. Picarella, M. Briskin, N. Buchanan, U.H. von Andrian, Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues, *J. Exp. Med.* 201 (2005) 303–316.
462. C. Lurquin, B. Lethe, E. De Plaen, V. Corbiere, I. Theate, N. van Baren, P.G. Coulie, T. Boon, Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen, *J. Exp. Med.* 201 (2005) 249–257.
463. A.F. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin, H. Hengartner, R.M. Zinkernagel, Immune surveillance against a solid tumor fails because of immunological ignorance, *Proc. Natl. Acad. Sci. U. S. A.* 96 (1999) 2233–2238.
464. U.H. von Andrian, C.R. Mackay, T-cell function and migration. Two sides of the same coin, *N. Engl. J. Med.* 343 (2000) 1020–1034.
465. Z.Z. Yang, A.J. Novak, M.J. Stenson, T.E. Witzig, S.M. Ansell, Intratumoral CD4⁺CD25⁺ regulatory T-cell-mediated suppression

- of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma, *Blood* 107 (2006) 3639–3646.
466. T. Ishida, R. Ueda, CCR4 as a novel molecular target for immunotherapy of cancer, *Cancer Sci.* 97 (2006) 1139–1146.
467. P. Kalinski, Y. Nakamura, P. Watchmaker, A. Giermasz, R. Muthuswamy, R.B. Mailliard, Helper roles of NK and CD8+ T cells in the induction of tumor immunity. Polarized dendritic cells as cancer vaccines, *Immunol. Res.* 36 (2006) 137–146.
468. T.W. Stone, L.G. Darlington, Endogenous kynurenines as targets for drug discovery and development, *Nat. Rev., Drug Discov.* 1 (2002) 609–620.
469. M. Friberg, R. Jennings, M. Alsarraj, S. Dessureault, A. Cantor, M. Extermann, A.L. Mellor, D.H. Munn, S.J. Antonia, Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection, *Int. J. Cancer* 101 (2002) 151–155.
470. D. Braun, R.S. Longman, M.L. Albert, A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation, *Blood* 106 (2005) 2375–2381.
471. D.Y. Hou, A.J. Muller, M.D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A.L. Mellor, G.C. Prendergast, D.H. Munn, Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses, *Cancer Res.* 67 (2007) 792–801.
472. B.F. Johnson, T.M. Clay, A.C. Hobeika, H.K. Lyerly, M.A. Morse, Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy, *Expert Opin. Biol. Ther.* 7 (2007) 449–460.
473. B.I. Rini, V. Weinberg, L. Fong, S. Conry, R.M. Hershberg, E.J. Small, Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy, *Cancer* 107 (2006) 67–74.
474. A. van Elsas, A.A. Hurwitz, J.P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, *J. Exp. Med.* 190 (1999) 355–366.
475. G.Q. Phan, J.C. Yang, R.M. Sherry, P. Hwu, S.L. Topalian, D.J. Schwartzentruber, N.P. Restifo, L.R. Haworth, C.A. Seipp, L.J. Freezer, K.E. Morton, S.A. Mavroukakis, P.H. Duray, S.M. Steinberg, J.P. Allison, T.A. Davis, S.A. Rosenberg, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 8372–8377.
476. C.F. LeMaistre, M.N. Saleh, T.M. Kuzel, F. Foss, L.C. Platanias, G. Schwartz, M. Ratain, A. Rook, C.O. Freytes, F. Craig, J. Reuben, J.C. Nichols, Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2, *Blood* 91 (1998) 399–405.

477. P. Attia, A.V. Maker, L.R. Haworth, L. Rogers-Freezer, S.A. Rosenberg, Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma, *J. Immunother.* 28 (1997) (2005) 582–592.
478. D. Gabrilovich, Mechanisms and functional significance of tumourinduced dendritic-cell defects, *Nat. Rev., Immunol.* 4 (2004) 941–952.
479. S. Kusmartsev, F. Cheng, B. Yu, Y. Nefedova, E. Sotomayor, R. Lush, D. Gabrilovich, All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination, *Cancer Res.* 63 (2003) 4441–4449.
480. R.A. Lake, B.W. Robinson, Immunotherapy and chemotherapy—A practical partnership, *Nat. Rev., Cancer* 5 (2005) 397–405.
481. P. Rovere, C. Vallinoto, A. Bondanza, M.C. Crosti, M. Rescigno, P. Ricciardi-Castagnoli, C. Rugarli, A.A. Manfredi, Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function, *J. Immunol.* 161 (1998) 4467–4471 (*America* 1992 Jul 1;89(13):6020–4).
482. M.E. Lutsiak, R.T. Semnani, R. De Pascalis, S.V. Kashmiri, J. Schlom, H. Sabzevari, Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide, *Blood* 105 (2005) 2862–2868.
483. N.J. Nessler, R.A. Sahota, B. Stone, K. Johnson, N. Chima, C. King, D. Rasmussen, D. Bishop, P.S. Rennie, M. Gleave, P. Blood, H. Pai, CLudgate, B.H. Nelson, Standard treatments induce antigen-specific immune responses in prostate cancer, *Clin. Cancer Res.* 13 (2007) 1493–1502.